GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy [Yahoo! Finance]
CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN)
US:NASDAQ Investor Relations:
collplant.com/investor-relation
Company Research
Source: Yahoo! Finance
pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related to the therapeutic developed by Dr. Adi Aran , renowned cannabinoid researcher. Dr. Aran will lead the clinical trial while Dr. Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study. Professor Burstyn-Cohen's lab is renowned for studying how microglia function in the regulation and maintenance of a healthy nervous system, and the consequences of any disruption of their function. The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model. The study's in vitro data demonstrated neuropro
Show less
Read more
Impact Snapshot
Event Time:
CLGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLGN alerts
High impacting CollPlant Biotechnologies Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CLGN
News
- CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business [Yahoo! Finance]Yahoo! Finance
- CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEPR Newswire
- COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE [Yahoo! Finance]Yahoo! Finance
CLGN
Earnings
- 11/29/23 - Miss
CLGN
Analyst Actions
- 4/5/24 - HC Wainwright
CLGN
Sec Filings
- 4/4/24 - Form 6-K
- 4/4/24 - Form 20-F
- 2/15/24 - Form 6-K
- CLGN's page on the SEC website